Blood · 2007 · 199 citations · 29 references
Life SciencesGeneticsMolecular GeneticsCytogeneticsGenomicsMolecular OncologyCancer CytogeneticsCancer GenomicsClinical CytogeneticsMolecular CytogeneticsPediatric Cancer GeneticsPediatric LeukemiasAcute LeukemiasAcute Lymphoblastic Leukemia BiologyArray CytogeneticsChildhood Cancer GenomicsClinical Cytogenetic DiagnosticsLeukemia CytogeneticsMicroarray AnalysisSingle-nucleotide Polymorphism Detection
Pediatric acute lymphoblastic leukemia (ALL) is a malignant disease resulting from accumulation of genetic alterations. A robust technology, single nucleotide polymorphism oligonucleotide genomic microarray (SNP-chip) in concert with bioinformatics offers the opportunity to discover the genetic lesions associated with ALL. We examined 399 pediatric ALL samples and their matched remission marrows at 50,000/250,000 SNP sites using an SNP-chip platform. Correlations between genetic abnormalities and clinical features were examined. Three common genetic alterations were found: deletion of ETV6, deletion of p16INK4A, and hyperdiploidy, as well as a number of novel recurrent genetic alterations. Uniparental disomy (UPD) was a frequent event, especially affecting chromosome 9. A cohort of children with hyperdiploid ALL without gain of chromosomes 17 and 18 had a poor prognosis. Molecular allelokaryotyping is a robust tool to define small genetic abnormalities including UPD, which is usually overlooked by standard methods. This technique was able to detect subgroups with a poor prognosis based on their genetic status.
29
A haplotype map of the human genome
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature · 2005 · 3.5K citations
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
Róbert Královics, Francesco Passamonti, Andreas Buser et al. · New England Journal of Medicine · 2005 · 3.5K citations · Full text
Life Sciences, Genetics, Hematology +15
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations
Life Sciences, Genetics, Hematology +14